Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) EBIT (2016 - 2025)

Perspective Therapeutics' EBIT history spans 16 years, with the latest figure at -$26.0 million for Q3 2025.

  • For Q3 2025, EBIT fell 39.36% year-over-year to -$26.0 million; the TTM value through Sep 2025 reached -$111.1 million, down 93.01%, while the annual FY2024 figure was -$90.9 million, 121.99% down from the prior year.
  • EBIT for Q3 2025 was -$26.0 million at Perspective Therapeutics, down from -$22.0 million in the prior quarter.
  • Across five years, EBIT topped out at $299000.0 in Q4 2021 and bottomed at -$45.0 million in Q4 2024.
  • The 5-year median for EBIT is -$9.8 million (2023), against an average of -$11.4 million.
  • The largest annual shift saw EBIT surged 134.25% in 2021 before it crashed 1979.93% in 2022.
  • A 5-year view of EBIT shows it stood at $299000.0 in 2021, then plummeted by 1979.93% to -$5.6 million in 2022, then tumbled by 107.72% to -$11.7 million in 2023, then crashed by 285.27% to -$45.0 million in 2024, then skyrocketed by 42.27% to -$26.0 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's EBIT are -$26.0 million (Q3 2025), -$22.0 million (Q2 2025), and -$18.2 million (Q1 2025).